drugset
drugset / Trial / NCT06468644

Phase II Study of Different Doses of Radiotherapy Combined With Sintilimab in the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06468644 ↗

Phase 2 Not yet recruiting 60 enrolled Fujian Cancer Hospital
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is aimed to evaluate the efficacy and safety of different doses of radiotherapy combined with sintilimab in locally advanced esophageal squamous cell carcinoma.

Timeline

Start
2024-06-17
Primary completion
2026-06
Completion
2027-06

Drugs

EvaluationDrugModalityDoseRoute
Background Cisplatin Other / unclassified 25 mg/m2 —
Background Paclitaxel Small molecule 150 mg/m2 —
Background Sintilimab Monoclonal antibody 200 mg Intravenous

Indications

esophageal squamous cell carcinoma